Caring for Patients with Opioid Use Disorder: Optimizing Interprofessional Care

Certificate Program

Note: The “Caring for Patients with Opioid Use Disorder: Optimizing Interprofessional Care” certificate program is hosted by the North Carolina Association of Pharmacists (NCAP).  Any questions regarding the program, or hosting the program in your state through their shared revenue model, should be directed to NCAP at

Click Here to Reach NCAP’s Registration Form


8-Hours of Joint-Accreditation provided by the American Society of Addiction Medicine (ASAM) for Pharmacists, Physicians, Doctors of Osteopathic Medicine, Physician’s Assistants, Nurse Practitioners, and Nurses.

See Joint Accreditation Statement Below for More Information

Target Audience

The target audience for this advanced level training include: physicians, nurse practitioners/nurses, physician assistants, and pharmacists.  Clinicians who see patients with addiction in primary care, emergency/urgent care, treatment center, or general psychiatry settings.




This is a comprehensive, one-time training program designed to furnish healthcare professionals with a thorough understanding of the prevention, detection and management of patients with substance use disorders. The program is designed to meet the MATE Act of 2023, 8-hour training requirements, based on DEA and SAMHSA curricular recommendations.

The program addresses prevention, treatment, and recovery conceptualizing substance use disorder as a chronic brain disease affected by genetic, behavioral, cultural and socioeconomic factors. The program will place an emphasis on opioid use disorder (OUD), and is designed to equip participants with the information needed to effectively treat and manage patients living with OUD.

Course Outcomes

This program covers a wide range of essential substance use disorder topics, including the epidemiology, pathophysiology, screening, and diagnosis of substance use disorders, as well as the pharmacology and pharmacotherapy for medications used in the treatment of OUD. Additionally, participants will learn to breakdown stigma and barriers, facilitate harm reduction, manage and support recovery in special populations, such as perinatal and mental health patients, as well as provide effective pain management in patients living with OUD.


A number of programs state “designed to meet MATE Act of 2023 requirements”. Two important standout reasons to support taking this program: The program was developed with the practitioner in mind, with a goal for participants to emerge knowing how to screen, treat and manage the care needs of patients with OUD. The program was developed by an interprofessional team of providers with a goal of having participants emerge from the program as champions of interprofessional models of care to achieve and support long-term recovery and wellness.

Global Objectives

  • Describe societal, cultural, behavioral, and economic factors that may lead to opioid use disorders (OUD).
  • Describe pathophysiological brain changes that lead to OUD.
  • Apply clinical guidelines to provide evidence-based medications for OUD (MOUD).
  • Evaluate the role of an interprofessional team, including those with lived experience, to treat persons with OUD.

Module 1:  Epidemiology, Definitions and Diagnosing, Pathophysiology, Screening and Stigma
In Module 1, the certificate program sets the stage by reviewing the epidemiology and pathophysiology of opioid use disorder (OUD). The interprofessional providers explain in detail the nuances of screening for and diagnosing OUD. They discuss stigma faced by patients with OUD and how to support this patient population from their robust firsthand experiences. With up-to-date trends and a deeper understanding of OUD as a chronic disease, listeners are prepared to jump into the next module to learn about pharmacotherapy options.

Module 2: Medications for Opioid Use Disorder
In Module 2, the certificate program dives deep into our three medications for opioid use disorder: methadone, naltrexone, and buprenorphine. A clinical pharmacist discusses the pharmacokinetics and pharmacodynamics of each medication along with each medications’ role in therapy. The listener can answer questions and walk through patient cases to further their clinical understanding. The module providers current and novel literature especially as it relates to buprenorphine inductions and access.

Module 3: Perinatal Opioid Use Disorder, Urine Drug Screens, and Harm Reduction
In Module 3 of the certificate program, we shift focus from treatment options to explore additional ways to support patients with opioid use disorder (OUD). We engage in an interactive discussion about perinatal opioid use disorder, aiming to challenge any preconceived notions about substance use during pregnancy and postpartum periods. The program also covers the purpose, function, and limitations of urine drug screens. Lastly, we introduce harm reduction as a crucial aspect of caring for individuals with OUD, emphasizing the theme of “meeting people where they are.”

Module 4: Models of Care and Recovery
In Module 4, the certificate program shows how team-based care can be the best practice for supporting patients with opioid use disorder (OUD). In the first section, a review of the different models of care illustrates success in various settings. A discussion on the components of recovery creates a framework for person-centered care. To close, the program echoes the voice of persons with lived experience and elevates the invaluable services of peer support specialists on the healthcare team.

Accreditation and Credit Designation Statements

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the NCAP and the American Society of Addiction Medicine. The American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity awards 8 Nursing contact hours.

This activity will offer 8 pharmacy contact hours (8 CEUs). Pharmacists will be asked to provide identifying information (e-Profile ID and DOB in MMDD format) in order to receive credit and allow reporting to CPE Monitor. (UAN: JA0000141-9999-24-050-H01-P)

ASAM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 8 AAPA Category 1 CME credits. Approval is valid until 5/1/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Credits
This activity was planned by and for the healthcare team, and learners will receive 8 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure Information

In accordance with disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed all financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

None of the planners, faculty, and staff have relevant financial relationships.